Target intelligence / Profile preview

Succinate dehydrogenase complex assembly factor 1 (SDHAF1)

Target
SDHAF1
Molecular classification
Chaperone protein, Assembly factor, Mitochondrial protein, Other
01

Overview

Succinate dehydrogenase complex assembly factor 1 (SDHAF1) is a small mitochondrial chaperone protein essential for the assembly and stability of succinate dehydrogenase (complex II), which plays a crucial role in both the TCA cycle and the mitochondrial electron transport chain[1][3][2]. SDHAF1 specifically facilitates the maturation of the iron-sulfur subunit (SDHB) of the SDH complex, protecting it from oxidative damage and enabling proper incorporation of iron-sulfur clusters by recruiting the iron-sulfur transfer complex (including HSC20 and ISCU)[1][2][3]. Mutations in the SDHAF1 gene have been associated with mitochondrial complex II deficiency and severe neurodegenerative disorders, most notably infantile leukoencephalopathy and, in rare cases, Leigh syndrome[1][4]. No known drugs directly target SDHAF1, but genetic testing for SDHAF1 mutations serves as a biomarker for certain mitochondrial diseases[1][3].

Other names
SDHAF1LYRM8Succinate dehydrogenase assembly factor 1, mitochondrialLYR motif-containing protein 8SDH assembly factor 1MC2DN2
02

Mechanism of action

Not applicable (no current drugs directly target SDHAF1)

03

Biological functions

Assembly of the succinate dehydrogenase (SDH) complex (complex II)Maturation and protection of SDHB (iron-sulfur subunit) from oxidative damageFacilitation of iron-sulfur cluster incorporation into SDHBMitochondrial electron transportTricarboxylic acid (TCA) cycle function
04

Disease associations

Mitochondrial complex II deficiencyLeukoencephalopathyLeigh syndrome (in some cases)Kearns-Sayre syndrome (rare associations)Other mitochondrial diseases
05

Safety considerations

None documented relating to pharmacologic targeting (since it is not currently a drug target). Mutations can cause severe infantile neurological disease and mitochondrial dysfunction.
06

Interacting drugs

None known (no drugs directly target SDHAF1 as a therapeutic mechanism)
07

Biomarkers

SDHAF1 gene mutations are used for diagnosis of SDHAF1-related mitochondrial complex II deficiency and infantile leukoencephalopathy

Beyond the preview

Go deeper on Succinate dehydrogenase complex assembly factor 1 (SDHAF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Succinate dehydrogenase complex assembly factor 1 (SDHAF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call